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Abstract: Introduction: Recurrence of primary sclerosing cholangitis (rPSC) after liver transplantation (OLT) signifi cantly aff ects long-
term graft survival. We aimed to evaluate the incidence of rPSC and clinical data of these patients in Hungary. Patients and Methods: 
We retrospectively analyzed data of 511 whole liver transplantations from 1995 to 2011. During the study period, 49 OLTs were performed 
in 43 adult patients with end-stage PSC (10%). Results: Out of 49 OLT, 24 cases were excluded, rPSC was diagnosed in six patients (12%). 
Patients with rPSC had signifi cantly higher mortality (p = 0.009) and graft loss (p = 0.009) in comparison to patients without recurrent disease. 
Younger recipient age, higher donor BMI was observed in the rPSC group. One patient was diagnosed with de novo IBD, the remaining fi ve 
patients had worsening IBD activity in the posttransplant period. PreOLT colectomy was performed in 21% of the control and none of the 
rPSC group. PostOLT colectomy was performed in two rPSC patients due to severe therapy resistant colitis. Conclusions: Recurrent PSC 
signifi cantly aff ects long-term mortality and graft loss. Younger age at OLT, higher donor BMI and severe active IBD may be associated with 
PSC recurrence. PreOLT total colectomy might have protective eff ect against rPSC.
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Introduction
Primary sclerosing cholangitis (PSC) is a chronic infl am-
matory liver disease of unknown etiology aff ecting the 
intra- and/or extrahepatic bile ducts. Liver transplanta-
tion (OLT) is the only eff ective therapy for PSC patients 
with end-stage liver disease [1]. As a result of increasing 
number of patients transplanted for PSC, recurrent PSC 
(rPSC) has become an important condition negatively 
aff ecting graft survival [2]. The prevalence of rPSC is 
about 20% (5.7–59%), depending on diagnostic proce-
dures and lengths of follow-up [2]. The diagnosis of 
recurrent PSC is diffi  cult because non-anastomotic bili-
ary stricturing is an aspecifi c reaction for many insults 
aff ecting the new graft [3]. To date, donor and recipi-
ent demography [4, 5], use of extended criteria donor 
(ECD) [6], associated active infl ammatory bowel dis-
ease (IBD) [4, 6], acute rejection (ARE) [2] have been 
proposed to be risk factors for rPSC. In our previous 
study, we have reported worsening IBD activity after 
OLT in PSC patients [7]. In this study, we evaluated the 
incidence of rPSC and clinical data of PSC patients that 
may contribute to disease recurrence in the Hungarian 
liver transplant population.
Patients and Methods
We retrospectively analyzed data of 511 whole liver 
transplantations from 1995 to 2011. During the study 
period, 49 OLTs were performed in 43 adult patients 
with end-stage PSC (10%). Recurrent PSC was diag-
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nosed by the diagnostic criteria of Graziadei et al. [3]. 
Out of 49 OLTs, 24 cases were excluded due to hepatic 
artery thrombosis/stenosis (N = 8), biliary anastomotic 
stricture (N = 5), non-anastomotic biliary stricture with-
in 90 days after OLT (N = 1), established ductopenic 
rejection (N = 3) and lacking follow-up interval mainly 
due to early death (N = 7). Based on radiological, his-
tological and clinical features, six patients had recurrent 
PSC (rPSC) (24%), the remaining 19 patients were con-
sidered as controls (no-rPSC, 76%). We used Mayo score 
(Disease Activity Index) to assess the severity of ulcer-
ative colitis (UC) before and after OLT [7].
Statistical analysis
We used SPSS statistics. Diff erences were accepted to be 
signifi cant if p < 0.05.
Results
Using strict inclusion and exclusion criteria, a total of 
25 PSC patients were included in this study, 16 males 
and 9 females. The mean age at OLT was 34.7 years 
(±11), the mean MELD score was 14.2 (±5). 76% (N = 
19) had associated IBD preOLT. De novo IBD was di-
agnosed in two patients. The median duration of IBD 
before OLT was 112 months (±100). Clinical data of 
rPSC and no-rPSC patients are shown in Table I. The 
mean MELD score (rPSC 15 ± 5 vs. nPSC 11 ± 4.4, 
p = NS), cold ischemic time (CIT) (rPSC 440 ± 121 vs. 
nPSC 482 ± 102, p = NS), warm ischemic time (WIT) 
(rPSC 57 ±  15 vs. nPSC 51 ± 13.5, p = NS), recipi-
ent gender (male recipient rPSC 50% vs. nPSC 68%, 
p = NS), type of perfusion (UW-Viaspan or HTK Cus-
todiol) (HTK rPSC 50% vs. nPSC 53%, p = NS), type 
of OLT ( piggyback or crossclamp) (crossclamp rPSC 
85%, vs. nPSC 82%, p = NS), type of biliary reconstruc-
tion (duct-to-duct or hepaticojejunostomy) (hepati-
cojejunostomy rPSC 33% vs. nPSC 32%, p = NS), im-
munosuppression therapy (tacrolimus or cyclosporin) 
( tacrolimus rPSC 68% vs. nPSC 74%, p = NS), incidence 
of CMV mismatch (rPSC 17% vs. nPSC 21%, p = NS) 
were similar in the two groups. Patients with evidence 
of rPSC had signifi cantly higher mortality and graft loss 
(Table I). In the rPSC group, none of the patients had 
colectomy prior to OLT, but two colectomies were in-
dicated due to severe therapy-resistant colitis after OLT. 
On the contrary, there were four colectomies in the 
control group during the preOLT setting. We observed 
worsening activity of associated IBD in all patients with 
recurrent PSC.
Discussion
Recurrent PSC has become an important condition after 
OLT [2]. The pathomechanism of both PSC and rPSC 
is unknown, therefore, no eff ective medical treatment is 
available to date [8]. Evaluating rPSC is a challenge due 
to diff erential diagnostic diffi  culties and limited number 
of patients. The incidence of rPSC was 12% in our co-
hort, which is similar to other reported results [5, 9]. 
Table I Clinical data of patients in the recurrent PSC and the control group
rPSC, N = 6 No-rPSC, N = 19 p
Donor age (years) 39 ± 14 35.5 ± 11 NS
Donor BMI (kg/m2) 24.8 ± 2 22.3 ± 2 NS
Recipient age (years) 27.7 ± 7 37 ± 12 NS
Retransplantation 2 (33%) 0 (0%) 0.009
Patiend death 2 (33%) 0 (0%) 0.009
Acute cellular rejection (ARE) 4 (67%) 8 (42%) NS
PreOLT IBD 5 (83%) 14 (73%) NS
Duration of IBD before OLT (years) 3.9 ± 6 11.5 ± 8 NS
Time of colectomy
PreOLT 0 (0%) 4 (21%)
PostOLT 2 (33%) 2 (10%) NS
No colectomy 4 (67%) 13 (68%)
Severity of IBD after OLT compared to preOLT*
Worsened 5/5 (100%) 5/10 (50%)
Improved 0/5 (0%) 1/10 (10%) NS
No change 0/5 (0%) 4/10 (40%)
*De novo IBD was diagnosed in one patients in each group
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Recently, it has clearly shown that rPSC has a major im-
pact on graft survival [1]. In this study, both graft loss 
and mortality were negatively aff ected by rPSC. Con-
fl icting results have been reported regarding risk fac-
tors for rPSC; however, almost none of these had been 
confi rmed by others [2]. In this study, we analyzed the 
clinical data of patients with or without rPSC, and we 
found that rPSC patients were approximately 10 years 
younger than those without rPSC. Higher donor BMI in 
the rPSC group may be in accordance with the fi ndings 
of Alabraba et al., who reported poor liver graft quality 
as a signifi cant risk factor for rPSC [6]. ARE seems to be 
associated with recurrent PSC, but it is not clear whether 
rPSC is a consequence of biliary injury caused by ARE, 
or a common pathological immunoregulatory process is 
responsible for ARE and rPSC [2]. High rate of ARE 
(67%) was observed among rPSC patients in this study; 
however, it was not signifi cant when compared with the 
control group (42%). The strongest association with re-
current PSC seems to be the presence of active IBD in 
the colon [2]. First reported by Vera et al., colectomy, 
before or during OLT, can prevent PSC recurrence in 
PSC/IBD [4]. Abberant homing of T cells and shared 
lymphocyte pool between the gut and the liver can ex-
plain this strong association [10]. In this study, none of 
the patients who developed rPSC underwent preOLT 
colectomy, postOLT colectomy was performed in two 
patients due to severe therapy resistant colitis, who de-
veloped rPSC later. On the contrary, there were four 
colectomies in the control group during the preOLT 
setting. All patients with rPSC suff ered severe IBD after 
OLT. In conclusion, total colectomy prior to OLT or 
early after liver transplantation seems to have a protective 
eff ect for PSC, and also a life-threatening intervention. 
Recurrent PSC signifi cantly aff ects long-term mortality 
and graft loss. Younger age at OLT, higher donor BMI 
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